{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:37:34Z","timestamp":1770748654884,"version":"3.50.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We investigated the effect of disease activity-guided dose optimization (DAGDO) of TNF inhibitor (TNFi) on disease activity and TNFi dose in PsA and axial spondyloarthritis (axSpA) patients with low disease activity (LDA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted in PsA and axSpA patients doing well on TNFi and eligible for TNFi DAGDO. Three different treatment periods were defined: (i) full dose continuation period, (ii) TNFi DAGDO period, and (iii) period with stable TNFi dose after DAGDO. A mixed-model analysis was used to estimate mean Disease Activity Score 28-joint count CRP (DAS28-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) during these periods, and a mean percentage of the daily defined dose (%DDD) was calculated as secondary outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three hundred and twenty-four patients (153 PsA and 171 axSpA) were included, with a mean of 6.5 DAS28-CRP and 6.4 BASDAI measurements and a median follow-up duration of 46 and 44\u2009months, respectively. A corrected difference of 0.06 (95% CI: \u22120.09, 0.21) in mean DAS28-CRP was found for the TNFi DAGDO period and 0.03 (95% CI: \u22120.14, 0.20) for the period with stable TNFi dose, compared with full dose continuation period. Differences for BASDAI were 0.03 (95% CI: \u22120.21, 0.27) and 0.05 (95% CI: \u22120.24, 0.34), respectively. The mean %DDD for the three treatment periods was for PsA 108%, 62% and 78%, and for axSpA 108%, 62% and 72%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DAGDO of TNFi reduces drug exposure and has no negative effects on disease activity in PsA and axSpA patients compared with full dose continuation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab741","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T20:30:14Z","timestamp":1633033814000},"page":"2307-2315","source":"Crossref","is-referenced-by-count":20,"title":["Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-034X","authenticated-orcid":false,"given":"Celia A J","family":"Michielsens","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"},{"name":"Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5320-5702","authenticated-orcid":false,"given":"Michelle L M","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"},{"name":"Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank H J","family":"van den Hoogen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"},{"name":"Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise M","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons A","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek Nijmegen"},{"name":"Department of Rheumatic Diseases, Radboud Institute for Health Sciences, Radboudumc Nijmegen , the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,2]]},"reference":[{"key":"2022060107552970600_keab741-B1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022060107552970600_keab741-B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/msc.1367","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients' perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Musculoskeletal Care"},{"key":"2022060107552970600_keab741-B4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"2022060107552970600_keab741-B5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022060107552970600_keab741-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2022060107552970600_keab741-B7","first-page":"CD010455","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","volume":"5","author":"Verhoef","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022060107552970600_keab741-B8","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"key":"2022060107552970600_keab741-B9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B10","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"2022060107552970600_keab741-B11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","article-title":"High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission","volume":"74","author":"Araujo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/039463201302600333","article-title":"Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse","volume":"26","author":"Chimenti","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2022060107552970600_keab741-B13","doi-asserted-by":"crossref","first-page":"e000395","DOI":"10.1136\/rmdopen-2016-000395","article-title":"Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis","volume":"3","author":"Huynh","year":"2017","journal-title":"RMD Open"},{"key":"2022060107552970600_keab741-B14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/RHU.0000000000000617","article-title":"Low doses of etanercept can be effective to maintain remission in psoriatic arthritis patients","volume":"24","author":"de Stefano","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2022060107552970600_keab741-B15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/art.41716","article-title":"Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022060107552970600_keab741-B16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Compan","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2022060107552970600_keab741-B17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acr.24184","article-title":"Tumour necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Lawson","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022060107552970600_keab741-B18","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"2022060107552970600_keab741-B19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"2022060107552970600_keab741-B20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratacos","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022060107552970600_keab741-B21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landewe","year":"2018","journal-title":"Lancet"},{"key":"2022060107552970600_keab741-B22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landewe","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","article-title":"Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2022060107552970600_keab741-B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13063-019-4000-5","article-title":"Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial","volume":"21","author":"Michielsens","year":"2020","journal-title":"Trials"},{"key":"2022060107552970600_keab741-B25","doi-asserted-by":"crossref","first-page":"e028517","DOI":"10.1136\/bmjopen-2018-028517","article-title":"Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial","volume":"9","author":"Uhrenholt","year":"2019","journal-title":"BMJ Open"},{"key":"2022060107552970600_keab741-B26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-eular.1354","article-title":"OP0138 Feasibility of progressive anti-TNF tapering in axial spondyloarthritis patients in low disease activity: results from the multicenter non-inferiority prospective randomized controlled trial spacing","volume":"80","author":"Lukas","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B27","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022060107552970600_keab741-B28","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","article-title":"How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simplified disease activity index?","volume":"74","author":"Fleischmann","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"2022060107552970600_keab741-B32","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","article-title":"Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022060107552970600_keab741-B34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3899\/jrheum.120594","article-title":"Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic","volume":"40","author":"Madsen","year":"2013","journal-title":"J Rheumatol"},{"key":"2022060107552970600_keab741-B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2022060107552970600_keab741-B36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2022060107552970600_keab741-B37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.39946","article-title":"Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review","volume":"69","author":"Tweehuysen","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022060107552970600_keab741-B38","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022060107552970600_keab741-B39","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"2022060107552970600_keab741-B40","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab741\/40832702\/keab741.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2307\/43891718\/keab741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2307\/43891718\/keab741.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:57:25Z","timestamp":1654070245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2307\/6380445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,2]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,2]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab741","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,2]]}}}